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With interest we have read this review article describing the current
knowledge and unanswered questions concerning the sentinel lymph
node (SLN) biopsy concept in cervical cancer (Cibula and McCluggage,
2019).
The authors emphasize that SLN biopsy without additional pelvic
lymph node (LN) dissection is an unreliable method of LN staging if
pathological ultrastaging of the SLN is not performed. The minimal
evaluation method should include processing of all SLNs in their en-
tirety and, if metastases are not identified on initial sections, ex-
amination of multiple levels and cytokeratin immunohistochemical
staining in order to detect as many macro- and micrometastases as
possible. The method proposed by the authors is slicing each SLN at
2mm intervals, embedding all tissue slices in paraffin blocks and cut-
ting paraffin sections at 200 micron intervals through the whole block
with at least 2 sections per level; one section from each level is stained
with H&E and one section with a cytokeratin antibody if no tumor is
seen on the H&E stained slides. Additional unstained sections available
at each level are useful in case there is a problem with the H&E or
cytokeratin stain.
Although this method is labor-intensive and time-consuming for
pathologists and laboratory staff, the authors hope that national and
international pathology societies will recommend standardized ultra-
staging protocols. However, till now it is still a matter of debate which
ultrastaging protocol should be the recommended standard.
The proposed methodology reminds us of the European guidelines
for SLN examination in breast cancer formulated in 2006 (Perry et al.,
2008). These guidelines recommended step-sections stained with H&E
at 150–200 μm intervals through the paraffin block in order to identify
all micrometastases over 0.2 mm. We have used this methodology for
SLN examination in patients with breast cancer for several years untill
the outcome data of two large randomized clinical trials were published
in 2011 (Giuliano et al., 2011; Weaver et al., 2011) showing that the
occult metastases found by step-sectioning of the SLN paraffin block
had no significant effect on recurrence or survival. A subgroup analysis
by Weaver et al. indicated that smaller metastases had less effect on
outcome than larger metastases (Weaver et al., 2009).
Based on the evidence of these trials, the Belgian Working Group for
Breast Pathology then recommended a minimal SLN evaluation pro-
tocol submitting tissue sections of the SLN that are not thicker than 2
mm and assuring that at least one microscopic section is examined
every 2 mm through the node (Colpaert and Lambein, 2012). Ad-
ditionally, the evaluation of three H&E stained sections of the block,
one from the surface and two step-sections at 500μm intervals, was also
recommended to detect all macrometastases -even if the gross sec-
tioning and paraffin embedding were suboptimal- and most of the
larger micrometastases.
As mentioned by Cibula and McCluggage (Cibula and McCluggage,
2019), cancers arising in different organs differ in biological behavior
making it impossible to extrapolate from one organ site to another.
However, as the authors state, vulvar cancer is probably close to
cervical cancer in terms of lymphatic spread, the presence of anato-
mically well-defined regional lymph nodes and the crucial importance
of lymph node involvement for patient prognosis. SLN biopsy is now
considered the standard of care in vulvar cancer since the publication of
the GROINSS-V-I study results (Van der Zee et al., 2008; Oonk et al.,
2010). In these studies, ultrastaging of the SLN was performed if no
tumor was found on routine histopathology: additional pairs of sections
were cut at 500μm interval or 3 pairs of sections/mm tissue. One sec-
tion of each pair was stained with H&E; if negative, cytokeratin im-
munohistochemistry was performed on the other section. This SLN
evaluation method proved its diagnostic accuracy for more than a
decade now and is still used today by the Groningen pathologists (home
town of the GROINSS-V studies; Harry Hollema, personal communica-
tion) despite the fact that the finding of small micrometastases (smaller
than 1mm) and even isolated tumor cells is considered important to
select the patients that should have additional groin treatment (Oonk
et al., 2010).
SLN biopsy has recently also appeared in international guidelines
regarding endometrial cancer, like the NCCN guideline. There is no
general recommendation for the ultrastaging of these SLN. A meta-
analysis of 55 studies with 4915 patients with endometrial cancer
showed similar sensitivity of the SLN biopsy in studies with and without
ultrastaging (Bodurtha Smith et al., 2017). The prognostic significance
of isolated tumor cells and micrometastases in endometrial cancer is
still unknown.
In cervical cancer, limited data are available about the importance
of micrometastases and isolated tumor cells for the prognosis and
management of patients (Cibula et al., 2012). More data on this prog-
nostic significance should be obtained from ongoing prospective trials
(SENTIX trial and SENTICOL III trial, results expected in 2020 and
2025, respectively). Hopefully, these trials will also examine the im-
portance of the size of the micrometastasis. If only the larger ones are
prognostically important e.g. larger than 500 μm, pathologists can
adapt their ultrastaging protocols to this knowledge.
Awaiting further evidence from these trials, the Belgian Working
Group for Gynecological Pathology agreed upon a method for SLN
evaluation in patients with cancer of vulva, cervix or endometrium:
- Indications for intra-operative examination are to be discussed with
the local surgeon. The therapeutic consequences of intra-operative
SLN results are highest in patients with cervical cancer. Both frozen
section and imprint cytology are optional depending on the ex-
perience of the pathologist.
- SLN should be sliced in 2mm sections and totally embedded.
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- A minimum of 3 levels of each paraffin block is examined with a
maximal interval of 500 μm between the levels. Each level is ex-
amined by H&E. If negative, pan-cytokeratin immunohistochemistry
is performed on at least one level.
The proposed method will detect all macrometastases and also the
larger micrometastases. It has the advantage of being less labor-in-
tensive and time-consuming than the method proposed by Cibula and
might therefore gain wider acceptance. It can be adapted if more con-
vincing evidence is emerging about the prognostic importance of low
volume SLN disease. Evidently, for patients included in the prospective
SENTIX and SENTICOL III trials, the specific trial protocols will be re-
spected.
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